Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the establishment of standard operating procedures for diagnostic testing, diagnostic consultation and staff training, procurement of equipment, smart internet of things, and logistics assistance. It also provides diagnostic outsourcing services comprising pathology tests; infectious disease diagnostic tests; and genetic reproduction and screening tests. In addition, the company offers routine diagnostic tests for chronic kidney, blood, autoimmune, endocrine metabolism, and other diseases. Further, it provides technology platforms, including AI + healthcare; high-throughput sequencing technology platform; PCR technology platform; digital pathology remote diagnosis platform; and other technology platforms. The company provides its services through independent clinical laboratories and on-site diagnostic centers. Yunkang Group Limited was founded in 2008 and is headquartered in Guangzhou, the People's Republic of China.
Frequently asked questions
What sector does Yunkang Group Ltd (2325) operate in?
Yunkang Group Ltd belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is Yunkang Group Ltd (2325) current stock price?
As of the latest data, Yunkang Group Ltd stock price is HK$0.45, with a previous close of HK$0.45.
What is Yunkang Group Ltd (2325) current market capitalization?
Yunkang Group Ltd market cap is approximately 260.48 million.
What is Yunkang Group Ltd (2325) EBITDA?
Yunkang Group Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 16.75 million.
Does Yunkang Group Ltd (2325) pay dividends?
No. Yunkang Group Ltd does not pay a dividend.
What is Yunkang Group Ltd (2325) beta (volatility) score?
Yunkang Group Ltd has a beta of -0.798, indicating lower volatility than the overall market.
